SEC Tracker
Get the app
MGNX · XBRL financial data

Macrogenics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (MGNX's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue1011*91111119*13227341*2133
Cost of goods and services sold00*0000*0000*——
Research and development3047*46524139*40413334*3539
General and administrative1213*15141428*119109*108
Operating income (loss)(36)(49)*(54)(58)54(53)*(43)(37)19(12)*(33)(14)
Interest expense00*100(0)*0134*54
Other income (expense)—year only———year only———year only——
Income tax expense (benefit)—year only—001*—00(1)*—0
Net income (loss)18(46)*(52)(56)56(15)*(41)(36)17(14)*(37)20
Earnings per share, basic USD per share0.28(0.74)*(0.84)(0.89)0.90(0.25)*(0.65)(0.57)0.27(0.22)*(0.58)0.31
Earnings per share, diluted USD per share0.28(0.75)*(0.84)(0.89)0.90(0.25)*(0.65)(0.57)0.27(0.22)*(0.58)0.31
Weighted average shares, basic millions of shares6262*62636363*63636363*6364
Weighted average shares, diluted millions of shares6261*62636363*63636363*6364

Balance sheet

CSV

Fiscal quarters (MGNX's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents901018084180183146131805767114
Accounts receivable25107694111369131025
Inventory11113099989—
Prepaid and other current assets9101091012878784
Total current assets291251203157222217182205232220183322
Property and equipment, net23222120191817151413112
Right-of-use asset252423232225242423232221
Total assets340298248201264262225245271257218345
Accounts payable3611575756543
Accrued liabilities252418242529282123221830
Total current liabilities5156565859565539444396109
Lease liability, non-current303030302933323232323130
Total liabilities146146142143144146145199204201197303
Accumulated deficit(1,057)(1,103)(1,155)(1,211)(1,154)(1,170)(1,211)(1,247)(1,230)(1,244)(1,281)(1,262)
Total stockholders' equity19415310658120116794767562143
Total liabilities and equity340298248201264262225245271257218345
Common shares outstanding (cover page) millions of shares626263636363636363646464

Cash flows

CSV

Fiscal quarters (MGNX's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)18(46)*(52)(56)56(15)*(41)(36)17(14)*(37)20
Stock-based compensation5*4*67*6*11*44*4*3*32*
Depreciation and amortization2*2*22*2*2*22*2*2*21*
Net cash from operating activities(35)*(28)*(46)(44)*60*(38)*(47)(47)*(30)*43*(36)(41)*
Purchases of property and equipment0*1*11*1*1*11*0*0*01*
Net cash from investing activities(34)*39*2547*36*41*10(38)*(20)*(66)*4528*
Proceeds from issuing common stock0*0*00*0*0*———year only——
Net cash from financing activities50*0*01*(0)*0*(0)70*0*0*(0)60*
Net change in cash(19)*11*(21)4*96*3*(37)(15)*(51)*(23)*947*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Macrogenics11433(41)*63.7M2.8 quarters 10-QJun 30, 2026
Inovio Pharmaceuticals320(18)*103.4M2.0 quarters 10-QJun 30, 2026
Volitionrx2.80.4(5.2)*13.6M0.5 quarters 10-QJun 30, 2026
Gyre Therapeutics4329(17)*111.5M3.4 quarters 10-QJun 30, 2026
Oncolytics Biotech4.1not reported(8.1)*127.5M0.5 quarters 10-QJun 30, 2026
Seres Therapeutics160.7(22)*9.9M0.7 quarters 10-QJun 30, 2026
XBiotech110not reported(4.5)*30.5M24.3 quarters 10-QJun 30, 2026
Oramed Pharmaceuticals15not reported(0.2)*41.6M80.5 quarters 10-QJun 30, 2026
Corbus Pharmaceuticals Holdings23not reported(30)*19.3M4.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.